Heuck 1997b.
Methods | Setting: Denmark, paediatric outpatient clinic Length of intervention period: 4 weeks Randomisation: yes, computer‐generated randomisation schedule Allocation concealment: unclear Design: crossover, 1 week washout period Masking: double blind Excluded: not stated Withdrawals: stated Baseline characteristics: comparable Jadad score=4 | |
Participants | 16 adolescents: 12M 4F Age range: 12.9‐16.6 years Inclusion criteria: Adolescents with mild to moderate asthma Requiring treatment with only beta2 agonists or low dose inhaled corticosteroids Exclusion criteria: Inhaled or oral steroids in month prior to study | |
Interventions | BUD: 200 mcg 2 actuations 2xdaily (800 mcg/d) Placebo: 2actuations 2xdaily Delivery device: MDI+Nebuhaler spacer |
|
Outcomes | Lower leg growth velocity by knemometry Serum carboxy‐terminal propetide of type 1 collagen (PICP) Serum carboxy‐terminal pyridinioline cross‐liked telopeptide of type 1 collagen (ICTP) Amino‐terminal propeptide of type III procollagen (PIIINP) Urinary concentration pyridinoline crosslinks (PYD) Urinary concentration deoxypyridinoline crosslinks (DPD) Insulin‐like growth factor I (IGF‐I) Insulin‐like growth factor binding protein‐3 (IGFBP‐3) Morning PEFR Evening PEFR Daily use of beta2 agonists | |
Notes | No reply from author to clarify details of randomisation method. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Unclear risk | B ‐ Unclear |